Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race

Novo Nordisk is showing signs of recovery after a difficult two-year stretch marked by profit warnings, leadership changes, and a sharp decline in its share price. The Danish pharmaceutical giant is gaining renewed investor confidence as its oral Wegovy weight-loss pill continues to outperform Eli Lilly’s newly launched Foundayo in early U.S. prescription trends.

The competition between Novo Nordisk and Eli Lilly remains intense as both companies fight for leadership in the rapidly expanding obesity drug market, which analysts estimate could exceed $100 billion in the United States by the end of the decade. While Lilly still dominates the injectable segment with Zepbound and Mounjaro, Novo is finding momentum through its oral treatment.

Novo Nordisk shares have rebounded roughly 35% from their March low, reflecting optimism that the company’s turnaround strategy is beginning to deliver results. Investors will closely monitor the company’s second-quarter earnings on August 5 for signs that its recovery is sustainable. Eli Lilly is also scheduled to release earnings on the same day, with analysts expecting continued strong sales from its blockbuster diabetes and weight-loss medications.

Recent prescription data from IQVIA indicates that oral Wegovy has maintained stronger demand than many analysts anticipated, outperforming Foundayo despite some data limitations related to Lilly’s distribution channels. Analysts say the early success of oral Wegovy has eased concerns that Lilly’s oral therapy would quickly dominate the market.

Still, Novo faces significant challenges. Lilly’s injectable Zepbound continues to lead the U.S. obesity treatment market, with weekly prescriptions more than twice those of Wegovy injections. Novo is also under pressure after a disappointing heart disease drug trial and ongoing concerns about future generic competition.

Adding another layer to the rivalry, Novo recently filed a U.S. lawsuit accusing Eli Lilly of misleading advertising by comparing products without including higher-dose Wegovy data. Lilly has denied the allegations. While analysts believe the legal battle may have limited commercial impact, it highlights Novo’s increasingly aggressive strategy as it seeks to strengthen its position.

Many analysts believe even a stable earnings report without another profit warning would signal that Novo Nordisk is moving beyond its recent setbacks and rebuilding confidence in its long-term growth prospects.